GlaxoSmithKline Pharmaceuticals slumped 4.5% to Rs 2,529.95 at 15:03 IST, with the stock extending its recent steep losses.
Meanwhile, the S&P BSE Sensex was up 74.99 points, or 0.34%, to 21,994.78
On BSE, so far 1,091 shares were traded in the counter, compared with an average volume of 11,776 shares in the past one quarter.
The stock hit a high of Rs 2,648.90 and a low of Rs 2,491.05 during the day. The stock hit a record high of Rs 3,054.40 on 3 March 2014. The stock hit a 52-week low of Rs 2,100 on 7 March 2013.
The stock had underperformed the market over the past one month till 28 February 2014, falling 10.87% compared with the Sensex's 7.57% rise. The scrip, however, outperformed the market in past one quarter, rising 4.94% as against Sensex's 4.4% rise.
The large-cap company has an equity capital of Rs 84.70 crore. Face value per share is Rs 10.
Shares of GlaxoSmithkline Pharmaceuticals (GSK Pharma) lost 17.13% in five trading days from a recent high of Rs 3,053.05 on 3 March 2014.
GlaxoSmithKline PLC said late on Sunday, 9 March 2014, that following the voluntary open offer undertaken by its subsidiary, GlaxoSmithKline Pte, it has increased its stake in GlaxoSmithKline Pharmaceuticals, from 50.7% to 75%. GlaxoSmithKline Pte accepted 20.61 million shares from the shareholders of GlaxoSmithKline Pharmaceuticals, representing 24.33% of the total shares outstanding through the open offer, which started on 18 February 2014 and ended on 5 March 2014. The offer of Rs 3,100 per share values the transaction at Rs 6400 crore.
GSK Pharma's net profit fell 15.61% to Rs 116.88 crore on 1.5% decline in total income to Rs 693.45 in Q4 December 2013 over Q4 December 2012.
GlaxoSmithkline Pharmaceuticals is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The company's product portfolio includes prescription medicines and vaccines. Its prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular diseases and respiratory diseases.
Powered by Capital Market - Live News
